CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 18 enrolled
Drug / intervention
BRIMOCHOL™ +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04774237
NCT04774237Phase 2Completed

A 3-Dose, Multicenter, Randomized, Double-Masked, Crossover Phase 2 Safety and Efficacy Study of BRIMOCHOL™ Topical Ophthalmic Solution vs. BRIMOCHOL™ F Topical Ophthalmic Solution vs. Monotherapy With Carbachol Topical Ophthalmic Solution in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia

Visus Therapeutics·interventional·Posted Mar 1, 2021·Updated Mar 27, 2026

In Brief

A Phase 2 clinical trial evaluating BRIMOCHOL™, BRIMOCHOL™ F, and 1 other intervention for Presbyopia. Completed, enrolled 18 participants across 3 sites.

Detailed Summary

Safety and Efficacy Study of BRIMOCHOL™ vs. BRIMOCHOL™ F vs. Carbachol Monotherapy Topical Ophthalmic Solutions in Subjects with Emmetropic Phakic and Pseudophakic Presbyopia

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPresbyopia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedMar 1, 2021
Enrollment StartMar 24, 2021
Primary CompletionOct 19, 2021
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 5.3 years ago

Interventions

BRIMOCHOL™drug

A single drop in each eye at a visit.

BRIMOCHOL™ Fdrug

A single drop in each eye at a visit.

Carbacholdrug

A single drop in each eye at a visit.